1187945-05-6

Basic information

• Product Name: Regorafenib Impurity 6
• Synonyms: Regorafenib Impurity 6;4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)picolinic acid
• CAS NO: 1187945-05-6
• Molecular Formula: C₂₀H₁₂ClF₄N₃O₄
• Molecular Weight: 469.7735928
• Mol File: 1187945-05-6.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 499.8±45.0 °C(Predicted)
• Appearance: /
• Density: 1.587±0.06 g/cm3(Predicted)
• PKA: 0.97±0.50(Predicted)
• CAS DataBase Reference: Regorafenib Impurity 6(CAS DataBase Reference)
• NIST Chemistry Reference: Regorafenib Impurity 6(1187945-05-6)
• EPA Substance Registry System: Regorafenib Impurity 6(1187945-05-6)

Safety Data

• Hazardous Substances Data: 1187945-05-6(Hazardous Substances Data)

Usage

Uses

4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)picolinic Acid -- Regorafenib Impurity 6

Upstream product

• 327-78-6 4-chloro-3-(trifluoromethyl)phenyl isocyanate 
• 53750-66-6 4-chloro-pyridine-2-carbonyl chloride 
• 98-98-6 2-Picolinic acid 
• 1187945-02-3 tert-butyl 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)picolinate 
• 1020173-15-2 tert-butyl 4-(4-amino-3-fluorophenoxy)picolinate 
• 220000-86-2 tert-butyl 4-chloropyridine-2-carboxylate 
• 5470-22-4 4-chloropicolinic acid 

Downstream Products

• 1333489-02-3 methyl 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)picolinate 
• 1333489-03-4 C₂₁H₁₂⁽²⁾H₃ClF₄N₄O₄ 
• 1333488-98-4 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluoro-phenoxy)-N-(methyl-d₃)picolinamide hydrochloride 
• 1333390-47-8 C₂₁H₁₂⁽²⁾H₃ClF₄N₄O₃*CH₄O₃S 
• 1333386-18-7 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)-3-fluorophenoxy)-2-(N-1',1',1'-trideuteromethyl)pyridine amide p-toluenesulfonate 
• 1255386-16-3 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)-3-fluorophenoxy)-2-(N-1',1',1'-trideuteromethyl)pyridine amide 

Relevant articles and documents

PREPARATION AND USE OF MOLECULAR SITE TARGETED AND ACTIVATED KINASE INHIBITOR

Disclosed are molecularly targeted and activated kinase inhibitors and use thereof. Specifically, a compound represented by the following formula A or a pharmaceutically acceptable salt thereof, wherein X is a polar and a non-polar uncharged amino acid such as alanine, proline or threonine; A is alanine; N is asparagine; PABC is -NH-phenyl-CH2-O-; and Z is a drug molecule; wherein the lactobionic acid residue, XAN and PABC are linked to each other by an amide bond; PABC is bonded to Z by an ester group, i.e., -OC(O)-. ????????Lacto-XAN-PABC-Z?????(Formula A)